1. Home
  2. BOXL vs OGEN Comparison

BOXL vs OGEN Comparison

Compare BOXL & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boxlight Corporation

BOXL

Boxlight Corporation

N/A

Current Price

$0.79

Market Cap

3.3M

ML Signal

N/A

Logo Oragenics Inc.

OGEN

Oragenics Inc.

N/A

Current Price

$0.58

Market Cap

2.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BOXL
OGEN
Founded
1985
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
2.7M
IPO Year
2015
2010

Fundamental Metrics

Financial Performance
Metric
BOXL
OGEN
Price
$0.79
$0.58
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
82.7K
56.3K
Earning Date
04-16-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$25,743,612.00
N/A
Revenue This Year
$2.70
N/A
Revenue Next Year
$5.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
26.37
N/A
52 Week Low
$0.50
$0.50
52 Week High
$10.15
$5.24

Technical Indicators

Market Signals
Indicator
BOXL
OGEN
Relative Strength Index (RSI) 37.74 45.32
Support Level $0.71 $0.56
Resistance Level $0.97 $0.65
Average True Range (ATR) 0.07 0.04
MACD 0.01 0.00
Stochastic Oscillator 32.75 35.34

Price Performance

Historical Comparison
BOXL
OGEN

About BOXL Boxlight Corporation

Boxlight Corp is a technology company that develops, sells, and services interactive solutions predominantly for the education market but also for the corporate and government sectors. The company currently designs, produces, and distributes interactive technologies, including interactive and non-interactive flat panel displays, LED video walls, media players, classroom audio and campus communication, cameras, and other peripherals for the education market and non-interactive solutions, including flat-panels, LED video walls, and digital signage for the enterprise market. It has three reportable segments - Europe, Middle East and Africa (EMEA), and North and Central America (Americas). The majority of revenue is derived from the sale of education technology products in the EMEA segment.

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Share on Social Networks: